Stryker Co. (NYSE:SYK) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. trimmed its stake in shares of Stryker Co. (NYSE:SYK) by 1.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 33,605 shares of the medical technology company’s stock after selling 558 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Stryker were worth $12,099,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of SYK. Assenagon Asset Management S.A. grew its holdings in Stryker by 15.6% in the third quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock valued at $3,722,000 after purchasing an additional 1,392 shares during the last quarter. Arkadios Wealth Advisors boosted its position in shares of Stryker by 23.0% in the 3rd quarter. Arkadios Wealth Advisors now owns 732 shares of the medical technology company’s stock worth $265,000 after buying an additional 137 shares in the last quarter. Strategic Blueprint LLC grew its stake in Stryker by 5.8% in the 3rd quarter. Strategic Blueprint LLC now owns 1,426 shares of the medical technology company’s stock valued at $515,000 after acquiring an additional 78 shares during the last quarter. Valmark Advisers Inc. increased its holdings in Stryker by 16.4% during the 3rd quarter. Valmark Advisers Inc. now owns 2,738 shares of the medical technology company’s stock valued at $989,000 after acquiring an additional 386 shares in the last quarter. Finally, Mutual Advisors LLC raised its position in Stryker by 9.0% during the third quarter. Mutual Advisors LLC now owns 5,562 shares of the medical technology company’s stock worth $2,002,000 after acquiring an additional 457 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SYK. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. Barclays increased their target price on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. The Goldman Sachs Group boosted their price target on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a report on Thursday, January 30th. Citigroup reaffirmed a “buy” rating and set a $450.00 price objective on shares of Stryker in a research note on Wednesday. Finally, Royal Bank of Canada raised their price target on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $422.15.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $389.10 on Friday. The stock has a market capitalization of $148.47 billion, a P/E ratio of 50.14, a PEG ratio of 2.93 and a beta of 0.96. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The business’s fifty day moving average price is $380.06 and its 200 day moving average price is $370.50. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the company posted $3.46 earnings per share. As a group, research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.